Quantum Biopharma (NASDAQ:QNTM) Announces Earnings Results

Quantum Biopharma (NASDAQ:QNTM) posted its quarterly earnings results on Thursday. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06), Zacks reports.

Quantum Biopharma Trading Down 7.2%

QNTM traded down $0.25 during trading on Thursday, hitting $3.23. 223,249 shares of the company traded hands, compared to its average volume of 298,039. The company has a market cap of $20.67 million, a PE ratio of -0.39 and a beta of 0.45. The stock’s 50-day simple moving average is $3.46 and its two-hundred day simple moving average is $4.08. Quantum Biopharma has a 1 year low of $2.07 and a 1 year high of $23.66.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on QNTM shares. Weiss Ratings lowered Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Wall Street Zen raised Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma currently has an average rating of “Sell”.

Institutional Trading of Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC acquired a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned about 0.27% of Quantum Biopharma as of its most recent SEC filing. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.